vaccine protection acquisition neutralization-resistant siv challenges rhesus monkeys 
preclinical studies human immunodeficiency virus type hiv- vaccine candidates typically shown post-infection virological control protection acquisition infection previously reported neutralization-sensitive virus challenges1- demonstrate vaccine protection acquisition fully heterologous neutralization-resistant simian immunodeficiency virus siv challenges rhesus monkeys adenovirus/poxvirus adenovirus/adenovirus-vector-based vaccines expressing sivsme543 gag pol env antigens resulted % greater reduction per-exposure probability infection45 repetitive intrarectal sivmac251 challenges rhesus monkeys protection acquisition infection showed distinct immunological correlates compared post-infection virological control required inclusion env vaccine regimen data demonstrate proof-of-concept optimized hiv- vaccine candidates can block acquisition stringent heterologous neutralization-resistant virus challenges rhesus monkeys 
